An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Trial Profile

An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Clevudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 08 Jul 2008 According to a Pharmasset media release, 80 percent of HBeAg- patients had undetectable HBV DNA 12 weeks after completing a 48-week course of therapy.
    • 16 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top